Extracellular contrast medium (ECCM) for use in the diagnosis of lesions, in which the ECCM is gadolinium-DTPA (dimeglumine salt / gadopenthetic acid), in which the ECCM must be used in combination with a specific contrast medium of lesion (LSCM), and in which the LSCM is selected from the group comprising 99mTc-Medronat, 99mTc-Sestamibi, 99mTc-ECD, 99mTc-MAG3, 111In-DTPY-octreotide, 111In-DTPAoctreotate, 18F-fluordeoxyglucose ( FDG), 18F-dopamine, 18F-L-DOPA, 18F-fluorcholine, 18F-fluormethylethylcholine, 18Ffluordihydrotestosterone, 68Ga-NODAGATOC, 68Ga-DOTYTOC and in which the individual contrast agents of the combination of ECCM and LSCM are contrast agents imaging method to be used in a multiple synthetic (polymodal) imaging procedure, wherein said imaging procedure is a fusion procedure selected from the group comprising PET-MRI and SPECT-MRTand in which a. the ECCM and the LSCM must be administered consecutively； or b. the ECCM and the LSCM must be administered simultaneously, and in which the LSCM is enriched in the lesion after 10 minutes and is retained there for at least 1 hour, and in which the imaging signals are interpolated immediately .Medio de contraste extracelular (ECCM) para la utilización en el diagnóstico de lesiones, en el que el ECCM es gadolinio-DTPA (sal de dimeglumina/ácido gadopentético), en el que el ECCM debe ser utilizado en combinación con un medio de contraste específico de lesión (LSCM), y en el que el LSCM es seleccionado de entre el grupo que comprende 99mTc-Medronat, 99mTc-Sestamibi, 99mTc-ECD, 99mTc-MAG3, 111In-DTPY-octreotida, 111In-DTPAoctreotato, 18F-fluordesoxiglucosa (FDG), 18F-dopamina, 18F-L-DOPA, 18F-fluorcolina, 18F-fluormetiletilcolina, 18Ffluordihidrotestosterona, 68Ga-NODAGATOC, 68Ga-DOTYTOC y en el que los agentes de contraste individuales de la combinación de ECCM y LSCM son agentes de contraste de formación de imágenes que se van a utilizar en un procedimiento de formación de imágenes sintético múltiple (polimodal
